Jeffrey G. Supko
Harvard University
211 Papers
2K Citations
Jeffrey G. Supko is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 48, co-authored 203 publications. Previous affiliations of Jeffrey G. Supko include Massachusetts Institute of Technology & Ohio State University.
Chat about Author
Papers
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
TL;DR: In consideration of the potential for acute hepatotoxic reactions to GM, as well as to the other benzoquinoid ansamycins based upon structural analogy, additional pharmacological and therapeutic information is required to ascertain whether these compounds are viable candidates for clinical development.
554
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,S. Gurubhagavatula,Ross A Okimoto,Brian W. Brannigan,Patricia L Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C Christiani,Jeffrey Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
547
•Journal Article
Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins
TL;DR: Preliminary results suggest that irinotecan may have an increasing role in the treatment of other solid tumors, including small and non-small cell lung cancer, cervical cancer, ovarian cancer, gastric cancer, and malignant gliomas.
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
Myrna R. Rosenfeld,Xiaobu Ye,Jeffrey G. Supko,Serena Desideri,Stuart A. Grossman,Steven Brem,Tom Mikkelson,Daniel I. C. Wang,Yunyoung C. Chang,Janice Hu,Quentin McAfee,Joy D. Fisher,Andrea B. Troxel,Shengfu Piao,Daniel F. Heitjan,Kay See Tan,Laura Pontiggia,Peter J. O'Dwyer,Lisa E. Davis,Ravi K. Amaravadi +19 more
TL;DR: Data establish that autophagy inhibition is achievable with HCQ, but dose-limiting toxicity prevented escalation to higher doses of HCQ.